Biocept's patented collection tubes now available from VWR for the safe transport of patient specimens containing both circulating cell-free DNA (cfDNA) and circulating tumor cells (CTCs) at room temperature SAN DIEGO , June 11, 2018 /PRNewswire/ -- Biocept, Inc .
Large prospective multi-center clinical trial designed to evaluate the impact of cancer biomarker detection and serial monitoring using liquid biopsy to improve the outcomes of patients with lung cancerPatient-founded research consortium of 25 global oncology centers to create large, well-annotated, uniformly collected biorepository of lung cancer patient blood samples
Data to be presented at Molecular Med Tri-Con Virtual Conference SAN DIEGO --(BUSINESS WIRE)--Feb. 16, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, will present data showing that its Target Selector™ molecular assay kit detects
Abstract published in the Journal of Molecular Diagnostics shows 200-1,000 times increase in assay sensitivity with the addition of Switch-Blocker technology SAN DIEGO --(BUSINESS WIRE)--Nov. 9, 2021-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and
SAN DIEGO , Oct. 5, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating cancer patients , announces results from a prospective study comparing its Target Selector™ cerebrospinal fluid testing to
SAN DIEGO , Nov. 20, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces the results of a study analyzing
Target Selector™ platform delivers 90% concordance and capability to rapidly detect EGFR, ALK, BRAF, and ROS1 alterations in non-small cell lung cancer patients
SAN DIEGO , Feb. 23, 2015 (GLOBE NEWSWIRE) -- Biocept , Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), today announced that its blood-based diagnostic, OncoCEE-BR™, was
Real-world retrospective study showed increased sensitivity for CNSide relative to standard cerebral spinal fluid (CSF) cytology in detecting leptomeningeal metastases SAN DIEGO --(BUSINESS WIRE)--Jun. 5, 2023-- Biocept, Inc . (NASDAQ: BIOC) (“Biocept” or the “Company”), a leading provider of
Companies to take next step following successful completion of feasibility studies PHILADELPHIA & REHOVOT, Israel & SAN DIEGO --(BUSINESS WIRE)-- Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, and Biocept, Inc.
